Carl Zeiss Meditec said up to 1,000 jobs worldwide could be cut over the next three years as part of a sweeping restructuring plan aimed at restoring profitability amid weakening financial performance. The medical technology company announced the measures after reporting a sharp decline in first-half fiscal 2025/26 earnings, with adjusted EBITA falling to €60.5 million from €112.6 million a year earlier and revenue dropping 5.7% to €991 million.

The company said the layoffs are part of a broader effort to improve annual earnings by more than €200 million by fiscal year 2028/29. Planned actions include reducing administrative and personnel costs, streamlining its product portfolio, optimizing procurement and supply chains, and relocating some research and development activities to lower-cost countries. Carl Zeiss Meditec said the cuts were necessary to remain competitive and preserve its ability to invest in future innovation and growth.

Executives pointed to geopolitical uncertainty, weak investment demand in the Americas, declining intraocular lens sales, and unfavorable currency effects as key factors behind the weaker results. The company also said it expects up to €150 million in one-time restructuring costs and investments tied to the transformation program through 2028/29.